Home / Tag Archives: ixekizumab

News: ixekizumab


Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3)

ixekizumab

Blauvelt A, et al. – This paper scrutinized the efficacy and safety of ixekizumab through 108 weeks of treatment for moderate-to-severe plaque psoriasis. It was concluded that ixekizumab was well tolerated. It illustrated persistent efficacy through 108 weeks. Methods The enrollees (N = 1346) were randomized 2:2:2:1 to 80 mg …

Read More »

Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis (Ixora-peds)

  Purpose The purpose of this study is to evaluate the safety and efficacy of ixekizumab in pediatric participants with moderate-to-severe plaque psoriasis. Condition Intervention Phase Plaque Psoriasis Drug: Ixekizumab Drug: Placebo Phase 3 Study Type: Interventional Study Design: Allocation: Randomized Intervention Model: Parallel Assignment Masking: Triple (Participant, Care Provider, …

Read More »

Assessing Patient Confidence in Biologic Medications

  Purpose In dermatology, biologic medications are used to treat conditions such as moderate-to-severe psoriasis. These medications generally function to decrease inflammation or disrupt the inflammatory cycle. Examples of biologic medications commonly used in dermatology include tumor necrosis factor-alpha (TNF-alpha), blockers/inhibitors (etanercept, infliximab, certolizumab pegol, golimumab), interleukin 12/23 blockers (ustekinumab) …

Read More »

A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis (SPIRIT-H2H)

  Purpose The main purpose of this study is to evaluate the effectiveness and safety of ixekizumab versus adalimumab in participants with psoriatic arthritis (PsA) who are biologic disease-modifying anti-rheumatic drugs (DMARD) naive. Condition Intervention Phase Psoriatic Arthritis Drug: Ixekizumab Drug: Adalimumab Phase 4 Study Type: Interventional Study Design: Allocation: …

Read More »

Biologics Anchoring Study

  Purpose Biologics are used to treat conditions such as moderate-to-severe psoriasis, a chronic condition that impairs quality of life as much or more than other major medical conditions. Biopharmaceuticals are medications which are are isolated from biological sources including microorganisms, animals or humans. These medications generally function to decrease …

Read More »